Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGD | P52209 | 1/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4807998 | 1.00 | PGD (0.43) | PGDSLC22A6FFAR3SMN1; SMN2GPR84 | |
| SCHEMBL3650683 | 0.79 | PGD (0.47) | PGDSLC22A6SMN1; SMN2GPR84MAPT | |
| SCHEMBL6607487 | 0.78 | PGD (0.40) | PGDSLC22A6FFAR3SMN1; SMN2GPR84 | |
| SCHEMBL6599751 | 0.78 | PGD (0.40) | PGDSLC22A6FFAR3SMN1; SMN2GPR84 | |
| SCHEMBL6607495 | 0.78 | PGD (0.40) | PGDSLC22A6FFAR3SMN1; SMN2GPR84 | |
| SCHEMBL6599755 | 0.78 | PGD (0.40) | PGDSLC22A6FFAR3SMN1; SMN2GPR84 | |
| SCHEMBL5681121 | 0.74 | TSHR (0.32) | TSHR | |
| SCHEMBL13746699 | 0.74 | TSHR (0.32) | TSHR | |
| SCHEMBL6805671 | 0.74 | PGD (0.50) | PGDSLC22A6SMN1; SMN2GPR84MAPT | |
| SCHEMBL6507188 | 0.74 | ALDH1A1 (0.31) | TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7317100-B2 | Epothilone derivatives | NOVARTIS AG (CH) | 2008-01-08 | — | — | US | disclosed |
| US-20060014796-A1 | Epothilone derivatives | DENNI-DISCHERT DONATIENNE | 2006-01-19 | — | — | US | disclosed |
| EP-1581536-A2 | EPOTHILONE DERIVATIVES | Novartis AG (CH) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004056832-A2 | EPOTHILONE DERIVATIVES | NOVARTIS AG (CH) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014796-A1 | Epothilone derivatives | CYP4A11, CYP51A1, EPOR | PGD 1932/4885SLC22A6 3201/4885FFAR3 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.